News

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...
Devdiscourse6d
Health Updates: Rising Illnesses and Drug Approvals
A roundup of health news includes Mexico's first screwworm myiasis case, rising measles cases in Texas, the launch of a new ...
Morningstar8d
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
“Dupixent is the first new targeted treatment ... of Digital Media Regeneron uses its media and investor relations website and social media outlets to publish important information about ...
Finanznachrichten8d
Sanofi Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy ... Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, ...
Morningstar8d
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent has the potential to improve outcomes ... Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including ...
Mena FN8d
Dupixent® (Dupilumab) Approved In The U.S. As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria (CSU)
“Dupixent is the first new targeted treatment ... Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including ...
pharmaphorum11d
Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...
Nasdaq8d
Regeneron and Sanofi Announce FDA Approval of Dupixent for Chronic Spontaneous Urticaria in Patients Aged 12 and Older
Dupixent is the first new targeted therapy ... Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including ...